Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 289,821Xls
2D Structure
Also known as: Sandostatin, 79517-01-4, Nsc672461, Sandostatin (tn), Acetic acid;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-n-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide, Octreotide acetate (usp)
Molecular Formula
C51H70N10O12S2
Molecular Weight
1079.3  g/mol
InChI Key
XQEJFZYLWPSJOV-UHFFFAOYSA-N

A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
acetic acid;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
2.1.2 InChI
InChI=1S/C49H66N10O10S2.C2H4O2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41;1-2(3)4/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64);1H3,(H,3,4)
2.1.3 InChI Key
XQEJFZYLWPSJOV-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O.CC(=O)O
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Compound 201 995

2. Compound 201-995

3. Compound 201995

4. Octreotide

5. Octreotide Acetate

6. Octreotide Acetate Salt

7. San 201 995

8. San 201-995

9. San 201995

10. Sandostatin

11. Sandostatine

12. Sandoz 201 995

13. Sandoz 201-995

14. Sandoz 201995

15. Sm 201 995

16. Sm 201-995

17. Sm 201995

18. Sms 201 995

19. Sms 201-995

20. Sms 201995

2.2.2 Depositor-Supplied Synonyms

1. Sandostatin

2. 79517-01-4

3. Nsc672461

4. Sandostatin (tn)

5. Acetic Acid;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-n-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

6. Octreotide Acetate (usp)

7. Schembl58453

8. Chembl2000504

9. Hms3748c05

10. Bcp04661

11. Nsc671663

12. Nsc-671663

13. Nsc-672461

14. Acetic Acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

15. D-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-threonyl-n-[(1r,2r)-2-hydroxy-1-(hydroxymethyl)propyl]-l-cysteinamide Cyclic (2-7)-disulfide Acetate

16. 10-(4-aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-n-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide Acetate

17. D06495

18. 10-(4-aminobutyl)-19-[(2-amino-3-phenyl-propanoyl)amino]-16-benzyl-7-(1-hydroxyethyl)-n-[2-hydroxy-1-(hydroxymethyl)propyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

19. D-phenylalanyl-l-hemicystyl-l-phenylalanyl-d-trytophyl-l-lysyl-l-threonyl-l-hemicystyl-l-threoninol, Acetate

2.3 Create Date
2005-03-26
3 Chemical and Physical Properties
Molecular Weight 1079.3 g/mol
Molecular Formula C51H70N10O12S2
Hydrogen Bond Donor Count14
Hydrogen Bond Acceptor Count16
Rotatable Bond Count17
Exact Mass1078.46161005 g/mol
Monoisotopic Mass1078.46161005 g/mol
Topological Polar Surface Area420 Ų
Heavy Atom Count75
Formal Charge0
Complexity1780
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count10
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 6  
Drug NameOctreotide acetate
Drug LabelOctreotide acetate injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered acetate solution for administration by deep subcutaneous (intrafat) or intravenous injection. Octreotide acetate, known...
Active IngredientOctreotide acetate
Dosage FormInjectable
RouteInjection
Strengtheq 0.2mg base/ml; eq 1mg base/ml; eq 0.1mg base/ml; eq 0.05mg base/ml; eq 0.5mg base/ml
Market StatusPrescription
CompanySun Pharm Inds; Teva Pharms Usa; Fresenius Kabi Usa; Sagent Pharms; Eurohlth Intl; Wockhardt Usa

2 of 6  
Drug NameSandostatin
PubMed HealthOctreotide (Injection)
Drug ClassesEndocrine-Metabolic Agent
Drug LabelSandostatin (octreotide acetate) Injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered lactic acid solution for administration by deep subcutaneous (intrafat) or intravenous injection. Octre...
Active IngredientOctreotide acetate
Dosage FormInjectable
RouteInjection
Strengtheq 0.2mg base/ml; eq 1mg base/ml; eq 0.1mg base/ml; eq 0.05mg base/ml; eq 0.5mg base/ml
Market StatusPrescription
CompanyNovartis

3 of 6  
Drug NameSandostatin lar
Active IngredientOctreotide acetate
Dosage FormInjectable
RouteInjection
Strengtheq 30mg base/vial; eq 10mg base/vial; eq 20mg base/vial
Market StatusPrescription
CompanyNovartis

4 of 6  
Drug NameOctreotide acetate
Drug LabelOctreotide acetate injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered acetate solution for administration by deep subcutaneous (intrafat) or intravenous injection. Octreotide acetate, known...
Active IngredientOctreotide acetate
Dosage FormInjectable
RouteInjection
Strengtheq 0.2mg base/ml; eq 1mg base/ml; eq 0.1mg base/ml; eq 0.05mg base/ml; eq 0.5mg base/ml
Market StatusPrescription
CompanySun Pharm Inds; Teva Pharms Usa; Fresenius Kabi Usa; Sagent Pharms; Eurohlth Intl; Wockhardt Usa

5 of 6  
Drug NameSandostatin
PubMed HealthOctreotide (Injection)
Drug ClassesEndocrine-Metabolic Agent
Drug LabelSandostatin (octreotide acetate) Injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered lactic acid solution for administration by deep subcutaneous (intrafat) or intravenous injection. Octre...
Active IngredientOctreotide acetate
Dosage FormInjectable
RouteInjection
Strengtheq 0.2mg base/ml; eq 1mg base/ml; eq 0.1mg base/ml; eq 0.05mg base/ml; eq 0.5mg base/ml
Market StatusPrescription
CompanyNovartis

6 of 6  
Drug NameSandostatin lar
Active IngredientOctreotide acetate
Dosage FormInjectable
RouteInjection
Strengtheq 30mg base/vial; eq 10mg base/vial; eq 20mg base/vial
Market StatusPrescription
CompanyNovartis

5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Gastrointestinal Agents

Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)


Antineoplastic Agents, Hormonal

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)